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Abstract
Although the over-expression of angiogenic factors is reported in diffuse large B-cell lymphoma (DLBCL), the poor
response to anti-VEGF drugs observed in clinical trials suggests that angiogenesis in these tumours might be driven by
VEGF-independent pathways. We show that sphingosine kinase-1 (SPHK1), which generates the potent bioactive
sphingolipid sphingosine-1-phosphate (S1P), is over-expressed in DLBCL. A meta-analysis of over 2000 cases revealed that
genes correlated with SPHK1 mRNA expression in DLBCL were signiﬁcantly enriched for tumour angiogenesis meta-
signature genes; an effect evident in both major cell of origin (COO) and stromal subtypes. Moreover, we found that S1P
induces angiogenic signalling and a gene expression programme that is present within the tumour vasculature of SPHK1-
expressing DLBCL. Importantly, S1PR1 functional antagonists, including Siponimod, and the S1P neutralising antibody,
Sphingomab, inhibited S1P signalling in DLBCL cells in vitro. Furthermore, Siponimod, also reduced angiogenesis and
tumour growth in an S1P-producing mouse model of angiogenic DLBCL. Our data deﬁne a potential role for S1P signalling
in driving an angiogenic gene expression programme in the tumour vasculature of DLBCL and suggest novel opportunities
to target S1P-mediated angiogenesis in patients with DLBCL.
Introduction
Despite the use of rituximab and chemotherapy (R-CHOP),
the survival of patients with diffuse large B-cell lymphoma
(DLBCL) remains poor with a signiﬁcant proportion of
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patients being refractory or relapsing after therapy [1, 2].
Gene expression proﬁling has identiﬁed two clinically dis-
tinct DLBCL subgroups, the activated B cell (ABC) and
germinal centre B cell (GCB) forms, characterised by dif-
ferent, therapeutically tractable, molecular abnormalities.
Gene expression proﬁling has also identiﬁed tumour
microenvironment-derived molecular signatures, including
the Stromal-2 signature that is reported to be enriched for
angiogenesis-associated genes [3].
Although there may be therapeutic beneﬁts in targeting
angiogenesis in DLBCL, the results of clinical trials of
bevacizumab, a monoclonal antibody against VEGFA, have
been disappointing. Although this drug was well tolerated
when delivered as a single agent in relapsed DLBCL [4] or
in combination with R-CHOP in ﬁrst-line treatment [5], a
phase III study of RA-CHOP (MAIN trial) was stopped due
to increased cardiotoxicity in the absence of any signiﬁcant
impact on progression-free survival [6]. One explanation for
the limited clinical efﬁcacy of bevacizumab in DLBCL is
that angiogenesis in DLBCL does not depend on VEGF; a
contention supported by studies showing that VEGF
expression does not correlate with micro-vessel density in
DLBCL [7, 8].
S1P is a bioactive sphingolipid metabolite which pro-
motes cell growth and survival and has been shown to be a
potent inducer of angiogenesis [9]. SPHK1, one of the two
isoenzymes responsible for the production of S1P, is over-
expressed in different cancers [10, 11]. Secreted S1P is a
ligand for a family of ﬁve G-protein-coupled S1P receptors
(S1PR1-5). Signalling through S1PR1 and/or S1PR3 has
been shown to stimulate DNA synthesis, chemotactic
motility and tube formation in endothelial cells and to induce
angiogenesis in vivo [12–15]. As with other potent bioactive
mediators, S1P levels are tightly regulated and controlled by
the balance between its generation and its degradation by
S1P lyase and S1P phosphatases [16]. Although it has been
suggested that SPHK1 might play a role in haematological
malignancies [17], it’s role in DLBCL remains to be
established [18]. Furthermore, the effects of S1P signalling
on the DLBCL microenvironment, including its inﬂuence on
the tumour vasculature, have not been explored.
In the present study, we have shown that the over-
expression of SPHK1 correlates with an angiogenic tran-
scriptional programme in DLBCL. We deﬁned an endo-
thelial cell transcriptional signature of S1P signalling and
used this to show that the expression of S1P target genes in
these cells was correlated with that of SPHK1 in primary
DLBCL. Moreover, Siponimod, a small-molecule func-
tional antagonist of S1PR1 [19], reversed S1P signalling
and reduced angiogenesis and tumour growth in an S1P-
producing mouse model of DLBCL. Our data suggest novel
opportunities to target S1P-mediated angiogenesis in
patients with DLBCL.
Materials and methods
Cells and tissues
Tonsils and DLBCL samples were obtained with informed
consent and ethical approval (REC_RG_HBRC_12-071).
DLBCL cases were reviewed by haematopathologists (ZR,
YLH, UZ). Isolation of tonsillar germinal centre (GC) and
blood-derived B cells was described before [20–22].
Endothelial cells (EC) were isolated from umbilical cords
(HUVEC) under informed consent (REC_RG_HBRC_14-
180) using collagenase treatment [23] and cultured in M199
media supplemented with 5% fetal bovine serum (FBS), 1%
glutamine, 1% penicillin/streptomycin (ThermoFisher Sci-
entiﬁc, Waltham, MA, USA) and 1% EC-growth supple-
ment (Caltag Medsystems, Buckingham, UK) at 37 °C/5%
CO2. HT, Karpas-442, OCI-LY1, OCI-LY7, SUDHL4,
SUDHL5, SUDHL6 are EBV-negative GC-DLBCL lines,
Farage is an EBV-positive GC-DLBCL line. OCI-LY3 and
U2932 are EBV-negative ABC-DLBCL lines. Lines were
from DSMZ (Braunschweig, Germany), OCI (Ontario,
Canada) or ATCC (Manassas, VA, USA) and were cultured
in RPMI1640 or IMDM (OCI-LY1, OCI-LY7) media
(ThermoFisher Scientiﬁc) supplemented with 10% FBS and
1% penicillin/streptomycin.
Mouse xenografts and ﬂow cytometry
3 × 106 SUDHL6 cells were injected subcutaneously into
NSG mice (Charles River Laboratories, Wilmington, MA,
USA). After 17 days (when tumour volume averaged 63
mm3) mice were randomised into two groups (each n= 4)
and treated orally with either vehicle (0.1% DMSO in 10%
2-hydroxypropyl-β-cyclodextrin; Cayman Chemical, MI,
USA) or 6 mg/kg Siponimod (Selleckchem.com, Munich,
Germany) every 48 h. Mice were culled when average
tumour volumes in control mice reached 400 mm3
(28 days). Organs were weighed, minced and incubated
with Liberase DL/Liberase TL and DNASEI (Roche, Basel,
Switzerland) [24]. Cell suspensions were labelled with
mouse CD31 and CountBright absolute counting beads
(Thermoﬁsher Scientiﬁc) and analysed by ﬂow cytometry
on LSRII and FACS diva 8 (BD, Franklin Lakes, NJ, USA).
Details of the other mouse models tested are in Supple-
mentary Materials and Methods. All mouse experiments
were done according to UK Home Ofﬁce guidelines.
S1P measurements
For intracellular S1P measurements, cell pellets were snap-
frozen in liquid nitrogen. For secreted S1P measurements,
SUDHL4 cells were cultured in serum-free RPMI (without
phenol-red) supplemented with 1% tissue-culture grade
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fatty acid-free BSA (Sigma-Aldrich., St Louis, MO, USA)
for indicated times. Supernatants were harvested into pre-
chilled HPLC grade methanol (Sigma-Aldrich) supple-
mented with Halt™ Protease and Phosphatase Inhibitor
Cocktail (ThermoFisher Scientiﬁc). S1P levels were quan-
tiﬁed by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS; 4000
QTRAP, AB Sciex, Framingham, MA, USA) as previously
described [25].
Treatment of cells
S1P (Sigma-Aldrich) was prepared as in Supplementary
Materials and Methods and as before [26]. Prior to treat-
ments, HUVEC were cultured in full media depleted of EC-
growth supplement for 16 h and stimulated with 0.5 µM S1P
(or control/vehicle) for 5 min to detect ERK1/2 activation or
for 4 h to detect S1P transcriptional targets. For S1P inhi-
bition, Sphingomab or isotype/control antibodies (LPath
Inc., San Diego, CA, USA) were incubated with S1P (at
150 μg/ml per μM of S1P) for 1 h prior to S1P stimulation.
For S1PR1 inhibition, HUVEC were treated with 100 nM
S1PR1 functional antagonists Siponimod/BAF312, Ozani-
mod/RPC1063 or Ponesimod/ACT-128800 (Selleckchem.
com) for 1 h prior to S1P stimulation.
Quantitative RT-PCR (Q-PCR)
RNA was extracted with RNeasy Mini kit including geno-
mic DNA removal with RNase-Free DNase Set (Qiagen,
Manchester, UK). cDNA was generated with qScript™
cDNA SuperMix (QuantaBio, Beverly, MA, USA). Gene
transcripts were quantiﬁed with commercial gene expres-
sion assays (ThermoFisher Scientiﬁc; Supplementary
Table 1a) [21]. The 2−ΔΔCT method was used to quantify
target expression relative to housekeeping control. The
normalized values are shown relative to the reference
sample that was set to a relative quantity value of 1.
Protein analysis
Immunoblotting was by standard methodology [20].
Detection was with enhanced chemiluminescence (ECL;
GE Healthcare, Chalfont St Giles, UK) on a ChemiDoc MP
(Bio-Rad, Watford, UK). Immunohistochemistry (IHC) was
on 4 µm FFPE sections and HUVEC grown on microscope
slides, using either citrate or EDTA buffer antigen retrieval
and 0.3% H2O2 and 5× casein blocking [26–28]. Slides
were incubated either overnight at 4 °C or for 1 h at room
temperature in primary antibodies in 0.05% PBS/Tween and
visualised with species-speciﬁc ImmPRESS kits, followed
by diaminobenzidine or ImmPACT NovaRED (Vector
Laboratories, Peterborough, UK) with haematoxylin
counterstain. DLBCL were stained for BCL6, CD10 and
IRF4, and deﬁned as either GCB or non-GCB type by Hans
algorithm [29]. A subset of DLBCL was also stained for
SPHK1, S1PR1, CXCL12, SELE, COL1A1 and MAP1B.
Mouse tumours were stained for Ki67, cPARP and
CXCL12. For CXCL12, a Mouse-on-Mouse block (Vector
Laboratories) was performed prior to incubation in casein.
cPARP- and Ki67- positive cells were enumerated in at least
10 high power ﬁelds per tumour. Photomicrographs were
acquired on a Nikon Eclipse E400 microscope with ×20 or
×40 objectives (NA 0.40 and 0.65) at room temperature and
a Nikon DS-Fi-1 camera. Supplementary Table 1b lists
antibodies used for immunoblotting and IHC.
RNAseq analysis
RNAseq was performed on 4 biological replicates of
HUVEC treated with S1P or vehicle/control for 4 h. Quality
control (RNA integrity number >7), library construction and
sequencing was performed by BGI Tech Solutions (Hong
Kong). RNA was hybridised to Illumina HiSeq 2000 plat-
form and data obtained using 10M clean reads.
Analysis of gene expression
RNAseq data were aligned to the hg19 human genome
using Rsubread aligner [30] and assigned to genes with
featureCounts function. Read counts normalised between
samples were converted to counts-per-million (CPM) reads
using the edgeR package in R [31]. RNAseq data for 32
ABC and 54 GCB DLBCL were from the controlled access
area of NIH database of genotypes and phenotypes (dbGaP;
accession code phs000532.v5.p2) [32]. The RNAseq data
for 4 GC B cell samples were from GEO (GSE45982) [33].
Differentially expressed genes were identiﬁed using edgeR
with p < 0.05 and read CPM > 1 in at least half of the
samples. Microarray data for 11 DLBCL and 10 GC B cell
samples were from GEO (GSE12453) [34] and analysed
with MAS5 algorithm of the Affymetrix Expression Con-
sole to generate expression levels for each probe set (GCOS
Signal). The MAS5 TGT was set to 100. The series matrix
expression and clinical data reported in Lenz et al. [3] were
downloaded from GEO (GSE10846). Meta-analysis of 11
different DLBCL datasets was performed as before [35].
Spearman test was used to correlate gene expression
between samples.
Statistics
Statistical tests are indicated in relevant sections. All
experiments were performed at least in triplicate, and for B
cells on at least three separate donors. Tests were con-
sidered statistically signiﬁcant if p < 0.05.
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Results
SPHK1 is over-expressed in the tumour cells of
DLBCL
To explore the contribution of S1P signalling to angio-
genesis in DLBCL, we examined the expression of
SPHK1, an enzyme which generates S1P from sphingo-
sine. We measured SPHK1 mRNA in published datasets,
comparing global gene expression in DLBCL with that in
normal GC B cells [32, 34]. SPHK1 mRNA levels were
signiﬁcantly higher in DLBCL compared to GC B cells
(Fig. 1a) and in both ABC- and GCB- DLBCL subtypes
when analysed separately (Fig. 1b).
We performed IHC using an antibody we previously
showed is speciﬁc for SPHK1 [26]. We found that SPHK1
was present in normal GC B cells, and in the tumour cells
of all 32 cases of DLBCL examined; including cases of
both GCB and non-GCB type deﬁned by the Hans algo-
rithm [29] (Fig. 1c; Supplementary Table 2). The intensity
of SPHK1 expression in tumour cells was variable but
was generally higher than in background of non-
malignant cells, including macrophages and small reac-
tive lymphocytes (not shown). Furthermore, in contrast to
the strong staining observed in tumour cells, SPHK1 was
either only weakly detectable or undetectable in EC of
most (27/31) evaluable cases (Supplementary Table 2;
Fig. 1c).
SPHK1 mRNA and protein were also expressed in
DLBCL lines (Fig. 1d). Because the catalytic activity of
SPHK1 is enhanced by its phosphorylation at Ser225 we
used an antibody speciﬁc for this phosphorylation site
[36, 26]. Immunoblotting with this antibody revealed that
SPHK1 was phosphorylated in all cell lines examined
(Fig. 1d; lower panel and Supplementary Fig. 1A). S1P
levels were signiﬁcantly higher in all six DLBCL cell
lines examined compared to normal B cells (Fig. 1e).
Because S1P is a ligand for S1P receptors present on the
cell surface, it was of interest to determine whether
DLBCL cells such as SUDHL4, which express SPHK1
and produce S1P intracellularly, can also secrete it. We
found that DLBCL cells readily export S1P outside the
cells reaching a maximum level of around 1 nM within 2
min (Fig. 1f).
Finally, we stained the DLBCL cases for S1PR1. We
found that S1PR1 was expressed on endothelial cells in all
32 cases and in tumour cells in 20/32 cases (Supple-
mentary Table 2, Supplementary Fig. 1B upper panels). In
keeping with this, Q-PCR revealed that some, but not all,
DLBCL cell lines expressed S1PR1 (Supplementary
Fig. 1B, lower panel). In primary tumours, there was no
relationship between tumour cell expression of S1PR1
and disease subtype.
SPHK1 expression is associated with an angiogenic
transcriptome in DLBCL
We next performed a meta-analysis of 11 primary DLBCL
gene expression datasets comprising over 2000 cases of
DLBCL [35]. For each dataset, genes were ordered by their
variance across the patient samples and the top 80% were
used to calculate the Spearman’s rank correlations for their
expression against that of SPHK1. The resultant p-values
and correlation matrices were merged across the 11 datasets
by taking the median values. A SPHK1-correlated gene set
was created by taking all genes which were present in six or
more datasets with a median p < 0.05. This identiﬁed 2236
genes positively correlated and 1658 genes negatively cor-
related with SPHK1 expression in DLBCL (Supplementary
Table 3). We noted that genes positively correlated with
SPHK1 included well known angiogenesis-associated
genes, such as VEGF and VEGFR (r= 0.28, p= 0.0001;
and r= 0.19, p= 0.0042, respectively). A gene ontology
(GO) analysis [37] also showed a signiﬁcant enrichment of
angiogenesis and vasculature functions among genes posi-
tively correlated with SPHK1 (Fig. 2a). To provide further
conﬁrmation of a relationship between SPHK1 expression
and angiogenesis, we utilised a published ‘tumour vascular
gene signature’ generated from a meta-analysis of more
than 1000 primary human cancers [38]. We found that
genes positively correlated with SPHK1 expression in
DLBCL were signiﬁcantly enriched for tumour vascular
signature genes (odds ratio (OR)= 7.92, p < 0.0001),
whereas genes negatively correlated with SPHK1 were
signiﬁcantly depleted for tumour vascular signature genes
(OR= 0.37, p < 0.0001; Fig. 2b).
Repeating the meta-analysis, we found that tumour vas-
cular signature genes were signiﬁcantly enriched among
genes positively correlated with SPHK1 expression in GCB
and ABC subtypes when analysed separately (both p <
0.0001; Supplementary Fig. 2). As a further check on the
association between SPHK1 and angiogenesis, we used two
further gene signatures of angiogenesis (the “Hallmark”
angiogenic signature, M5944, and the signature for the GO
term ‘angiogenesis’). For both alternative angiogenic gene
sets, we again found a signiﬁcant overlap with genes
positively correlated with SPHK1 (both p < 0.0001, not
shown). Finally, we directly compared the mRNA expres-
sion of SPHK1 with that of classical EC markers in a further
published RNAseq dataset reported by Morin et al. [32], not
included in our original meta-analysis. This revealed a
signiﬁcant positive correlation between the expression of
SPHK1 and that of CD34, CDH5, PECAM1/CD31 and
VWF (Fig. 2c; Supplementary Fig. 3).
We also used the same 11 primary DLBCL datasets
described above to perform a meta-analysis of genes corre-
lated with S1PR1 in DLBCL. In keeping with the observed
L. Lupino et al.
strong expression of S1PR1 in the tumour vasculature of
DLBCL, we found that genes positively correlated with
S1PR1 in primary tumours were also signiﬁcantly enriched
for tumour vascular signature genes (OR= 7.92, p < 0.0001;
not shown). Furthermore, we also found that S1PR1 was
positively correlated with CD34, (Spearman test, r= 0.48; p
Fig. 1 SPHK1 is over-expressed
in primary DLBCL. a SPHK1
mRNA expression in the re-
analysis of a published
microarray dataset [34] and b
SPHK1 mRNA expression in
the re-analysis of published
RNAseq data [32]. c IHC for
SPHK1 protein expression in
normal GC B cells and also in
the tumour cells of
representative cases of DLBCL.
Arrows indicate tumour-
associated EC which did not
express SPHK1 (lower middle
and lower right panels). GC
germinal centre, MZ mantle
zone. Original magniﬁcations
×200 and ×600. d Upper panel:
qPCR analysis for the
expression of SPHK1 mRNA in
DLBCL cell lines. Data are in
triplicate and each is
representative of three separate
biological replicates. Lower
panel: Immunoblotting of
DLBCL cell lines for
phosphorylated and total
SPHK1 (pSPHK1, tSPHK1). β-
tubulin is a loading control. e
Intracellular S1P levels in
primary B cells and DLBCL cell
lines. Data show means (± SEM)
of four biological replicates.
Statistics were based on a
comparison of individual cell
lines with B cells#2. *Denotes p
< 0.05, **p < 0.01, ***p < 0.001
(Student’s t-test). f S1P levels
secreted by SUDHL4 cells
incubated in serum-free media
for indicated times measured by
mass spectrometry. Data show
means (± SEM) of three
biological replicates. *Denotes
p < 0.05
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< 0.0001), CDH5 (r= 0.42; p < 0.0001), PECAM1 (r=
0.46; p < 0.0001), and VWF (r= 0.44; p < 0.0001) in the
dataset reported by Morin et al. [32].
We conclude that the expression of both SPHK1 and
S1PR1 is associated with an angiogenic transcriptome
in DLBCL.
Fig. 2 SPHK1 expression is
associated with an angiogenic
transcriptome in primary
DLBCL. a Enrichment of
angiogenesis-related terms (red
arrows) in a GO analysis of
genes positively correlated with
SPHK1 expression in primary
DLBCL. The top 10 signiﬁcant
GO categories are shown
ordered by p-value. b Tumour
vascular signature genes [38]
were signiﬁcantly enriched
among genes positively
correlated with SPHK1
expression in primary DLBCL
(left panel), but signiﬁcantly
depleted among those negatively
correlated with SPHK1
expression in primary DLBCL
(right panel) (Fisher’s exact test
for both comparisons). c Re-
analysis of gene expression from
primary DLBCL [32] reveals a
statistically signiﬁcant positive
correlation between SPHK1
expression and the expression of
EC marker genes CD34, CDH5,
PECAM1 and VWF (r=
Spearman rank correlation
coefﬁcient)
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SPHK1 expression is associated with angiogenesis in
both Stromal-1 and Stromal-2 DLBCL subtypes
Given that angiogenesis was reported to be associated with the
Stromal-2 signature in DLBCL [3], we next explored the
correlation of SPHK1 expression with the expression of stro-
mal signature genes [3]. First, we studied the extent to which
Stromal-2 genes overlapped with the angiogenic gene sig-
natures. As expected, we found a signiﬁcant overlap of
Stromal-2 signature genes, but only with two of the three
angiogenic gene sets (Fig. 3a; upper panel). Consistent with
this, we found that SPHK1 expression was positively corre-
lated with Stromal-2 gene expression (calculated as the aver-
age expression across genes in the Stromal-2 signature [3]
(Spearman correlation= 0.46 and 0.47 for CHOP- and R-
CHOP-treated patients, respectively; p < 0.0001, not shown).
However, when we repeated this analysis, this time using
Stromal-1 signature genes [3], we were surprised to ﬁnd that
SPHK1 expression was even more highly correlated with
Stromal-1 gene expression (Spearman correlation= 0.80 and
0.77, respectively, p < 0.0001) and included a highly sig-
niﬁcant overlap with all three angiogenic gene sets (Fig. 3b;
lower panel). In contrast, we observed that S1PR1 expression
was positively correlated only with Stromal-2 gene expression
(Spearman correlation= 0.34 and 0.45 for CHOP- and R-
CHOP-treated patients, respectively; both p < 0.0001), and not
with Stromal-1-gene expression (Spearman correlation r=
0.02, p= 0.807; and r= 0.09, p= 0.212, for CHOP- and R-
CHOP-treated patients, respectively). We conclude that genes
positively correlated with SPHK1 are enriched in both stromal
signatures of DLBCL, most likely reﬂecting the contribution
of SPHK1 to angiogenesis in both stromal subgroups.
An in vitro transcriptional signature of S1P
signalling in endothelial cells
With the aim of revealing a more direct association between
S1P signalling and angiogenesis in DLBCL, we next
Fig. 3 Both Stromal-1 and Stromal-2 gene signatures are enriched for angiogenic genes. a Overlap between Stromal-2 genes and genes comprising
the three different angiogenic gene signatures. b Overlap between Stromal-1 genes and the angiogenic gene signatures
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deﬁned a transcriptional signature of S1P signalling in EC.
To do this we used human umbilical vein endothelial cells
(HUVEC) which we showed express the same pattern of
S1P receptors as the EC of DLBCL, marked by the high
expression of S1PR1 and the absence of S1PR2 and S1PR3
in most cases (Fig. 4a). We showed that S1P treatment of
HUVEC induced the robust phosphorylation of ERK1/2, a
well-deﬁned downstream target of S1P signalling in EC
[12] (Fig. 4b).
We next used RNAseq to describe the global transcrip-
tional consequences of S1P signalling in HUVEC. Treat-
ment of HUVEC with S1P was followed by the up-
regulation of 115 genes and the down-regulation of 126
genes (Supplementary Table 4). We used Q-PCR to validate
a subset of the genes which were both upregulated by S1P
and positively correlated with SPHK1 in our meta-analysis,
including IL-8, ICAM1, SELE, PDGFA, ANGPTL4 and
CXCL12 (Fig. 4c).
To conﬁrm the speciﬁcity of these effects, we repeated
these experiments in the presence of Sphingomab, a
monoclonal antibody which depletes extracellular S1P [39].
Sphingomab greatly suppressed S1P-induced phosphoryla-
tion of ERK1/2 (Fig. 4d) and the upregulation of its
downstream transcriptional targets (Fig. 4e). In contrast,
S1P induced the phosphorylation of ERK1/2 and the up-
regulation of its target genes in the presence of the isotype
control antibody.
Genes upregulated by S1P signalling and correlated
with SPHK1 mRNA are expressed in the tumour
vasculature of DLBCL
A gene ontology analysis revealed that genes upregulated
by S1P in HUVEC were signiﬁcantly enriched for GO
terms associated with angiogenesis, and for GO terms
associated with the known effects of S1P in EC, including
protection from apoptosis, leukocyte adhesion and migra-
tion (Fig. 5a). Furthermore, genes up-regulated (OR= 4.30,
p < 0.0001), but not those downregulated (OR= 0.78, p=
0.48), by S1P were signiﬁcantly enriched among genes
positively correlated with SPHK1 in DLBCL (Fig. 5b, left
panel). Similarly, genes downregulated (OR= 2.58, p <
0.0001), but not those up-regulated (OR= 0.73, p= 0.48),
by S1P were signiﬁcantly enriched in genes negatively
correlated with SPHK1 (Fig. 5b, right panel). The enrich-
ment of upregulated S1P targets among genes positively
correlated with SPHK1 was also evident when the GCB and
ABC subtypes were analysed separately (Supplementary
Fig. 4).
To provide direct evidence of the expression of S1P
target genes in the tumour vasculature of DLBCL we per-
formed IHC for CXCL12 and SELE, as well as COL1A1
and MAP1B, two further genes up-regulated in S1P-treated
HUVEC, positively correlated with SPHK1 expression in
DLBCL, and that had available antibodies that work
robustly in FFPE tissues. We found that all four markers
were expressed in the EC of both subtypes of DLBCL. In
contrast, tumour cells were either negative (CXCL12,
COL1A1, SELE) or showed only weak expression
(MAP1B) (Supplementary Table 5). In summary, these data
provide evidence of an S1P-regulated transcriptional pro-
gramme in the tumour vasculature of DLBCL.
S1PR1 inhibition reverses S1P signalling in vitro and
reduces angiogenesis and tumour growth in a
mouse model of angiogenic DLBCL
Finally, we explored the effects of inhibiting S1P sig-
nalling in a mouse model of DLBCL. We initially studied
ERK1/2 phosphorylation in vitro following the stimula-
tion of HUVEC with S1P, in the presence or absence of
Siponimod, Ozanimod and Ponesimod, three functional
antagonists of S1PR1 [19, 40, 41]. We found that all three
drugs decreased ERK1/2 phosphorylation in HUVEC,
conﬁrming their ability to reduce the effects of S1P on
downstream signalling (Fig. 6a). We next studied the
impact of inhibiting S1P signalling in a mouse model of
angiogenic DLBCL, focussing on Siponimod, a potent
functional antagonist of S1PR1 and S1PR5 (EC50:0.39
and 0.98 nM, respectively) with > 1000-fold selectivity
for S1PR1 versus S1PR2, S1PR3 and S1PR4 [42]. For
these experiments we used SUDHL6 cells, not only
because they produce high levels of S1P (Fig. 1e), but
also because as xenografts they induce levels of angio-
genesis that are almost 8-fold-higher than those found in
xenografts of OCI-LY1 cells, and nearly 60-fold higher
than those observed in the A20 syngeneic mouse model of
DLBCL (Supplementary Fig. 5A). We treated established
xenografts of SUDHL6 cells with Siponimod for up to
two weeks before culling the animals and measuring
mouse EC numbers in tumours by ﬂow cytometry. We
found that compared to controls, treatment of Siponimod
signiﬁcantly reduced the numbers of CD31-positive
mouse EC in tumour tissues (Fig. 6b) as well as redu-
cing their expression of the S1P target gene, CXCL12
(Supplementary Fig. 5B). Furthermore, Siponimod led to
a signiﬁcant reduction in tumour volumes in treated ani-
mals at the later time points (Fig. 6c) that was associated
with increased numbers of apoptotic cells as measured by
immunohistochemistry for cleaved PARP (Supplementary
Fig. 5C). In contrast, we did not observe signiﬁcantly
reduced tumour volumes following Siponimod treatment
of xenografts of the poorly angiogenic OCI-LY1 and A20
lines (Supplementary Fig. 5D, E). We conclude that the
inhibition of S1P signalling can reduce angiogenesis and
tumour growth in a mouse model of angiogenic DLBCL.
L. Lupino et al.
Fig. 4 Identiﬁcation of S1P
target genes in endothelial cells.
a Representative images of IHC
for S1PR1, S1PR2 and S1PR3
in primary DLBCL and
HUVEC. DLBCL-associated
EC (left and middle panels) were
positive for S1PR1 and negative
for S1PR2 and S1PR3 in most
cases (black arrows). Red blood
cells stained strongly for S1PR2
(red arrows) and served as an
internal positive control. S1PR3-
positive tumour cells (bottom
left) and/or squamous
epithelium (not shown) were
internal positive controls for
S1PR3 expression. HUVEC
(right panel) were positive for
S1PR1 and negative for S1PR2
and S1PR3. Original
magniﬁcations ×200 (tissues)
and ×600 (cells). b S1P
treatment of HUVEC increased
ERK1/2 phosphorylation, shown
here for 4 separate donors
compared with vehicle only
treated cells (H1-H4). β-tubulin
is a loading control. The same
protein lysates were used to
detect phosphorylated and total
ERK1/2 (pERK1/2, tERK1/2) in
separate blots. c Q-PCR for S1P
transcriptional targets in
HUVEC of four donors
following treatment with S1P
(dark grey bars) compared with
vehicle (light grey bars)
normalised to 1. *Denotes p <
0.05, **p < 0.01, ***p < 0.001
(Student’s t-test). d
Immunoblotting for pERK1/2,
tERK1/2 and β-tubulin in
HUVEC representative of three
donors treated with S1P in the
presence of Sphingomab
(SmAb) or isotype/control
antibody (CmAb). The same
protein lysates were used to
detect pERK1/2 and tERK1/2 in
separate blots. e Q-PCR for S1P
targets following treatment of
HUVEC with S1P in the
presence of either SmAb or
CmAb. Data shown are
representative of three donors.
*Denotes p < 0.05, **p < 0.01,
***p < 0.001 (Student’s t-test)
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Fig. 5 Genes upregulated by
S1P and correlated with SPHK1
mRNA are expressed in DLBCL
tumour vasculature. a GO
analysis of genes upregulated by
S1P in HUVEC revealed a
signiﬁcant enrichment of GO
terms associated with
angiogenesis. b Genes
upregulated (left panel), but not
those downregulated (not
shown) in S1P-treated HUVEC
were enriched among genes
positively correlated with
SPHK1 expression in primary
DLBCL. Genes downregulated
(right panel), but not those
upregulated (not shown) in S1P-
treated HUVEC were enriched
among genes negatively
correlated with SPHK1
expression in primary DLBCL. c
Representative examples of the
expression of the S1P target
genes, CXCL12, SELE,
COL1A1 and MAP1B, in the
tumour vasculature of DLBCL.
Original magniﬁcations ×200
L. Lupino et al.
Discussion
Although previous studies have shown that targeting VEGF
or its receptors can decrease tumour vascularization and
reduce the growth of DLBCL-derived cell lines in vivo, a
phase III trial of patients with aggressive NHL receiving R-
CHOP plus bevacizumab showed cardiotoxicity without
improvement in progression-free survival [6]. We specu-
lated that DLBCL-associated angiogenesis could be driven
by VEGF-independent signalling; a contention supported
by other studies which reveal no correlation between lym-
phoma cell VEGF expression and micro-vessel density in
primary DLBCL [7, 8]. Here, we have focused on the
potential contribution of the potent bioactive sphingolipid
metabolite, S1P. We have shown that SPHK1, the major
enzyme responsible for the production of S1P, which can be
secreted, is over-expressed in DLBCL. SPHK1 is strongly
implicated in tumour angiogenesis in other tumours [43],
and is important for the generation of S1P that drives
tumour-induced hemangiogenesis and lymphangiogenesis
in murine models of breast cancer [44]. The underlying
mechanisms responsible for the over-expression of SPHK1
in DLBCL are not known but do not usually involve
ampliﬁcation and/or mutation; our review of ﬁve separate
cohorts of DLBCL has revealed that the frequency of
ampliﬁcation and/or mutation of the SPHK1 gene is very
low (<1%; not shown; TCGA Research Network: http://ca
ncergenome.nih.gov/; [32, 45–47]).
SPHK1 can be activated by growth factors and cytokines
[48–52], and its catalytic activity is enhanced by ERK1/2-
mediated phosphorylation at Ser225 [36]. The pSer225
antibody used in our study showed that SPHK1 was con-
stitutively phosphorylated at Ser225 in DLBCL cell lines. In
keeping with this, we showed that S1P production was
increased in DLBCL cell lines compared to normal B cells,
and furthermore that this S1P was secreted into the extra-
cellular environment.
Our meta-analysis of DLBCL revealed a strong correla-
tion between the expression of SPHK1 and that of angio-
genesis meta-signature and EC-classiﬁer genes. One
explanation for this ﬁnding could be expression of SPHK1
in tumour-associated EC. However, we observed SPHK1
expression predominantly in cancer cells, consistent with
the notion that SPHK1 expression is upregulated primarily
in the tumour cell population [18].
Although the meta-analysis and our in situ expression
data suggested that angiogenesis in DLBCL is driven by
tumour-derived SPHK1, these approaches do not directly
implicate S1P. Interactions between tumour and EC medi-
ated by S1P have been shown to be important for angio-
genesis in many solid cancers, including those of the breast,
prostate, liver and kidney [53–55]. To investigate the
involvement of S1P in DLBCL-associated angiogenesis, we
deﬁned a transcriptional signature of S1P signalling in
HUVEC [23]. Gene ontology analysis revealed that genes
up-regulated in this transcriptional signature were enriched
Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B. . .
for angiogenesis-associated GO terms, as well as for GO
terms reﬂecting known functions of S1P [9, 12, 13, 56, 57].
We used this transcriptional signature to show that genes
upregulated by S1P were enriched among genes correlated
with SPHK1, an association that was also evident separately
for both COO subtypes. IHC revealed that S1P target genes
were expressed in the tumour vasculature of SPHK1-
expressing DLBCL, with little or no tumour cell expression,
suggesting that the enrichment of S1P target genes observed
in SPHK1-expressing DLBCL was primarily a consequence
of their expression in tumour-associated EC.
Recent studies exploring the transcriptional landscape of
DLBCL have deﬁned tumour microenvironment-derived
gene signatures predicting clinical outcome [2, 3]. The
‘Stromal-1’ signature, associated with a favourable out-
come, is characterised by expression of extracellular matrix-
and macrophage-associated genes. In contrast, the ‘Stromal-
2’ signature has an unfavourable outcome, and is reportedly
enriched for angiogenesis-associated genes [3]. We for-
mally tested the relationship between angiogenesis and
these stromal signatures [3]. As expected, we found a sig-
niﬁcant enrichment of angiogenesis-associated genes within
the Stromal-2 signature. However, we were surprised to ﬁnd
an even stronger enrichment of angiogenesis genes within
the Stromal-1 signature. Both stromal signatures were
enriched for genes positively correlated with SPHK1
expression, suggesting that SPHK1 contributes to angio-
genesis in both stromal subtypes.
Our data suggest novel therapeutic opportunities for
patients with SPHK1-expressing DLBCL insofar as the
S1PR1 functional antagonists, Siponimod, Ozanimod and
Ponesimod, were all able to block S1P signalling in EC.
Although we observed the same effect with the S1P-speciﬁc
monoclonal antibody, Sphingomab, we suggest that S1PR1 is
a preferred target; S1P-blocking agents will affect signalling
through all S1P receptors. Potentially unwanted side-effects of
blocking S1P could include the inhibition of
S1PR2 signalling which we and others have reported to be
tumour suppressive in DLBCL [58, 59, 60]. Moreover, we
showed that Siponimod, a highly potent functional antagonist
of S1PR1 that is effective and safe in patients with multiple
sclerosis [61], can reduce angiogenesis and tumour growth of
SUDHL6 xenografts which produce S1P and which we used
as a mouse model of angiogenic DLBCL. Targeting tumour
cell over-expression of S1PR1, which is observed in a subset
of poor prognosis DLBCL, is also potentially advantageous,
since S1PR1 has been shown to be important for the pro-
liferation and survival of DLBCL [62, 63]. S1P/
S1PR1 signalling also promotes the accumulation of Treg
while inhibiting CD8+T cell recruitment and activation in
xenograft models of breast cancer and melanoma [64].
Therefore, blocking S1PR1 might also promote anti-tumour
immunity. Taken together our observations suggest that spe-
ciﬁc S1PR1 antagonists should be investigated for their
therapeutic potential in DLBCL patients [40, 65, 66].
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